ERBB2 and neoplasm: Genomic features that associated with response to chemotherapy in HER2− tumours, and usually correlated with proliferation, included TP53 mutations, tumour mutation burden, BRCA, HRD and APOBEC mutational signatures, and chromosomal instability.